Safety profile of Ayurvedic poly‑herbomineral formulation - Bacnil capsule in albino rats.
Acute toxicity
bacnil
polyherbomineral formulation
safety
Journal
Ayu
ISSN: 0974-8520
Titre abrégé: Ayu
Pays: India
ID NLM: 7605807
Informations de publication
Date de publication:
Historique:
received:
17
04
2018
revised:
26
06
2018
accepted:
28
02
2020
entrez:
7
12
2020
pubmed:
1
7
2019
medline:
1
7
2019
Statut:
ppublish
Résumé
Bacnil capsule is a poly‑herbomineral formulation used to treat gastroenteritis. It contains many potential drugs derived from plant sources and The study was designed to ascertain the safety of bacnil capsule orally in Charle's Foster albino rats. As per the Organization for Economic Cooperation and Development (OECD) 425 protocol oral acute toxicity study, bacnil capsule was administered orally once only at the dose of 2000 mg/kg in rats. For repeated dose toxicity study, AYUSH 170 and OECD 407, it was administered at three dose levels, Therapeutic doses (TED) (196.2), TED × 5 (981) and TED × 10 (1962) mg/kg/day orally for 28 days in albino rats followed by a 15‑day recovery period only on TED × 10 dose level. Bacnil at the oral dose of 2000 mg/kg did not produce any toxicity or mortality in albino rats. Repeated dose 28‑day oral toxicity revealed that test formulation did not produce any significant change in serum biochemical, hematological, and histopathological parameters at therapeutic dose level. Mild‑to‑moderate pathological changes were observed in the various serum biochemical and cytoarchitecture of the liver, heart, kidney, and stomach at a dose of 10 TEDs; however, the same was reversed after discontinuation in the recovery test. Bacnil at 196.2 mg/kg/day is safe at the therapeutic dose level in albino rats.
Identifiants
pubmed: 33281396
doi: 10.4103/ayu.AYU_64_18
pii: AYU-40-185
pmc: PMC7685255
doi:
Types de publication
Journal Article
Langues
eng
Pagination
185-191Informations de copyright
Copyright: © 2020 AYU (An International Quarterly Journal of Research in Ayurveda).
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Clin Chem. 1974 Apr;20(4):447-53
pubmed: 4818198
Clin Chem. 1974 Nov;20(11):1458-60
pubmed: 4421368
Clin Chem. 1973 May;19(5):522-4
pubmed: 4703662
Scand J Clin Lab Invest. 1965;17(4):381-7
pubmed: 5838275
Evid Based Complement Alternat Med. 2017;2017:4365429
pubmed: 28316635
Gastroenterol Hepatol (N Y). 2011 Oct;7(10):695-6
pubmed: 22298965
J Ethnopharmacol. 2005 Aug 22;100(1-2):53-6
pubmed: 16026949
Front Pharmacol. 2014 Jan 10;4:177
pubmed: 24454289
Z Klin Chem Klin Biochem. 1974 May;12(5):226
pubmed: 4440114
Clin Chem. 1969 Jun;15(6):487-95
pubmed: 5786804
Mol Aspects Med. 2006 Feb;27(1):1-93
pubmed: 16105678
J Ethnopharmacol. 2012 Jun 26;142(1):98-104
pubmed: 22561344
Clin Chim Acta. 1973 Oct 12;48(2):193-201
pubmed: 4758882
Klin Wochenschr. 1965 Feb 1;43:174-5
pubmed: 14258517
Clin Chem. 1983 Mar;29(3):538-42
pubmed: 6825269